• Je něco špatně v tomto záznamu ?

Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia

DJ. Kuter, J. Mayer, M. Efraim, LH. Bogdanov, R. Baker, Z. Kaplan, M. Garg, M. Trněný, PY. Choi, AJG. Jansen, V. McDonald, R. Bird, J. Gumulec, M. Kostal, T. Gernsheimer, W. Ghanima, A. Daak, N. Cooper

. 2024 ; 8 (7) : 1715-1724. [pub] 20240409

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, klinické zkoušky, fáze I, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014350

Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 × 109/L in all patients, 68 × 109/L in those who had rilzabrutinib monotherapy (n = 5), and 156 × 109/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of ≥50 × 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts ≥30 × 109/L and ≥50 × 109/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 × 109/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals. This trial is registered at www.clinicaltrials.gov as #NCT03395210 and www.clinicaltrialsregister.eu as EudraCT 2017-004012-19.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014350
003      
CZ-PrNML
005      
20240905134335.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023012044 $2 doi
035    __
$a (PubMed)38386978
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kuter, David J $u Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA $1 https://orcid.org/0000000320848810
245    10
$a Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia / $c DJ. Kuter, J. Mayer, M. Efraim, LH. Bogdanov, R. Baker, Z. Kaplan, M. Garg, M. Trněný, PY. Choi, AJG. Jansen, V. McDonald, R. Bird, J. Gumulec, M. Kostal, T. Gernsheimer, W. Ghanima, A. Daak, N. Cooper
520    9_
$a Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 × 109/L in all patients, 68 × 109/L in those who had rilzabrutinib monotherapy (n = 5), and 156 × 109/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of ≥50 × 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts ≥30 × 109/L and ≥50 × 109/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 × 109/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals. This trial is registered at www.clinicaltrials.gov as #NCT03395210 and www.clinicaltrialsregister.eu as EudraCT 2017-004012-19.
650    _2
$a lidé $7 D006801
650    12
$a idiopatická trombocytopenická purpura $x farmakoterapie $x chemicky indukované $7 D016553
650    _2
$a výsledek terapie $7 D016896
650    _2
$a receptory Fc $7 D011961
650    _2
$a thrombopoetin $x terapeutické užití $7 D013926
650    12
$a trombocytopenie $x chemicky indukované $7 D013921
650    _2
$a krvácení $x chemicky indukované $7 D006470
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic $1 https://orcid.org/0000000305679887 $7 nlk20000083651
700    1_
$a Efraim, Merlin $u University Multiprofile Hospital for Active Treatment "St. Marina" - Varna, Varna, Bulgaria $1 https://orcid.org/0000000165706643
700    1_
$a Bogdanov, Lachezar H $u Clinic of Hematology, University Hospital, Pleven, Bulgaria
700    1_
$a Baker, Ross $u Perth Blood Institute, Murdoch University, Perth, Australia $1 https://orcid.org/0000000227286788
700    1_
$a Kaplan, Zane $u Monash Medical Centre, Clayton, Australia $1 https://orcid.org/0000000176899997
700    1_
$a Garg, Mamta $u Leicester Royal Infirmary, Leicester, United Kingdom $1 https://orcid.org/0000000235600132
700    1_
$a Trněný, Marek $u First Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000269526073 $7 nlk20000083659
700    1_
$a Choi, Philip Y $u Canberra Hospital, Garran, Australia $1 https://orcid.org/0000000193408125
700    1_
$a Jansen, A J Gerard $u Erasmus MC, University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/0000000226121420
700    1_
$a McDonald, Vickie $u Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom $1 https://orcid.org/0000000343928223
700    1_
$a Bird, Robert $u Princess Alexandra Hospital, Woolloongabba, Australia $1 https://orcid.org/0000000231101424
700    1_
$a Gumulec, Jaromir $u Department of Hemato-Oncology, University Hospital, Ostrava, Czech Republic $u Department of Hemato-Oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/000000030449942X $7 xx0054104
700    1_
$a Kostal, Milan $u Fourth Department of Internal Medicine and Hematology, Faculty of Medicine, University Hospital of Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000206865852
700    1_
$a Gernsheimer, Terry $u University of Washington and Fred Hutchinson Cancer Center, Seattle, WA $1 https://orcid.org/0000000226715608
700    1_
$a Ghanima, Waleed $u Østfold Hospital Foundation, Gralum, Norway and Institute of Clinical Medicine, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000322256165
700    1_
$a Daak, Ahmed $u Sanofi, Cambridge, MA $1 https://orcid.org/0000000221226813
700    1_
$a Cooper, Nichola $u Department of Immunology and Inflammation, Imperial College, London, United Kingdom $1 https://orcid.org/0000000298458292
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 7 (2024), s. 1715-1724
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38386978 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134328 $b ABA008
999    __
$a ok $b bmc $g 2143869 $s 1226216
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 7 $d 1715-1724 $e 20240409 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace